Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise

Admin—April 28, 20250

The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) is seen on the facade of the company’s Munich headquarters on August 29, 2024 in Munich (Bavaria).

Matthias Balk | Picture Alliance | Getty Images

Bristol Myers Squibb‘s earnings beat and rosy outlook Thursday did not resolve lingering issues for the stock. But it was enough, for now.

Corporate sponsors are backing away from LGBTQ+ Pride organizations

German fiscal boost won’t outweigh tariff drag for euro zone, IMF’s Europe head says

Why we’re lowering our Bristol Myers price target despite an earnings beat, guidance raise

Shares of DocuSign surge 14% on strong earnings, AI boost

American Eagle stock soars 20% as retailer says Sydney Sweeney campaign is ‘best’ to date, beats earnings

Lululemon shares plunge 20% as it slashes earnings outlook, projects $240 million tariff hit

Week in review: How we navigated the strong market ahead of the big Fed meeting

HPE CEO Neri pleased with quarter despite AI revenue delays as stock bounces from post-earnings dip

Week in review: Stocks rise, Meta gets real on metaverse, and Salesforce bounces

Rubrik stock rips 22% higher after blowing out earnings and boosting guidance

$208 million wiped out: Yieldstreet investors rack up more losses as firm rebrands to Willow Wealth

Bessent says U.S. will finish the year with 3% GDP growth, sees ‘very strong’ holiday season

HPE CEO Neri pleased with quarter despite AI revenue delays as stock bounces from post-earnings dip

David Ellison’s hunt for WBD made David Zaslav richer — and it may not be over

London’s answer to Wall Street gains momentum as major firms sign on

Ukraine, trade, pandas: What China’s Xi and France’s Macron discussed in Beijing